MECHANISM
OF ACTIION

Xiidra has a mechanism of action that blocks the interaction of ICAM-1 and LFA-11

Lifitegrast, the active ingredient in Xiidra, is designed to specifically block the interaction of ICAM-1 and LFA-1, which is a key mediator of the inflammation behind Dry Eye Disease.1-3

In vitro studies have shown that Xiidra may inhibit the recruitment of previously activated T cells, the activation of newly recruited T cells, and the release of pro-inflammatory cytokines—interrupting the perpetual cycle of inflammation.1,4

The exact mechanism of action of Xiidra in Dry Eye Disease is not known.1

Important Safety Information

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.

References

  1. Xiidra [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.

  2. Gao J, Morgan G, Tieu D, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj÷grens syndrome-like MRL/lpr mice. Exp Eye Res. 2004;78(4):823-835.

  3. Zhang Y, Wang H. Integrin signalling and function in immune cells. Immunology. 2012;135(4):268-275.

  4. TFOS DEWS II Research Subcommittee. Report of the Research Subcommittee of the Tear Film & Ocular Surface Society Dry Eye WorkShop II (2017). Ocul Surf. 2017;15(3):269-275.